iCAD Announces Poster Presentation of Xoft System to Treat Skin Cancer Highlighted at 2013 American Brachytherapy Society Annual

  iCAD Announces Poster Presentation of Xoft System to Treat Skin Cancer
  Highlighted at 2013 American Brachytherapy Society Annual Meeting

 Positive Data Show Xoft a Good Alternative to Surgery for Non-Melanoma Skin
Cancer with No Recurrences and Good Cosmetic Outcomes after One Year Follow Up

Business Wire

NEW ORLEANS -- April 18, 2013

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced that positive data in
support of the Company’s Xoft^® Axxent^® Electronic Brachytherapy System^® to
treat non-melanoma skin cancer (NMSC) were highlighted in a poster
presentation today at the 2013 American Brachytherapy Society (ABS) Annual
Meeting being held from April 18-20, 2013 in New Orleans.

Ajay Bhatnagar, MD, MBA, Department of Radiation Oncology, School of Medicine
at the University of Pittsburgh, and Co-Director of Cancer Treatment Services
in Casa Grande, Ariz. presented clinical outcomes data on 172 patients with
247 NMSC lesions treated with high-dose-rate (HDR) electronic brachytherapy
with surface applicators, using the Xoft System. Data on earlier follow-up on
this patient cohort was published in the journal Brachytherapy in March/April
2013.

“HDR electronic brachytherapy is a convenient, non-surgical treatment option
for non-melanoma skin cancer, especially for hard to reach lesions on the tip
of the nose, eyelids and behind the ear. The data presented today demonstrate
good cosmetic results, low toxicity and, most importantly, no recurrence at
one year and more from treatment,” said Dr. Bhatnagar. “The Xoft System allows
us to drastically reduce treatment time, making it an ideal option for elderly
patients.”

“We are encouraged by the data presented on the Xoft System for non-melanoma
skin cancer, as it further demonstrates the system’s effectiveness,” said Ken
Ferry, President and CEO of iCAD. “Increased evidence of improved clinical
outcomes combined with shorter treatment times and the system’s mobility are
contributing to the rapid adoption of the Xoft System.”

About Non-Melanoma Skin Cancer
NMSC, identified as either basal cell carcinoma or squamous cell carcinoma, is
not only the most common type of skin cancer, it is the most common type of
cancer in humans. These cancers commonly appear on sun-exposed areas of the
body such as the face, ears, neck, lips, and backs of the hands. NMSC affects
approximately 2.2 million Americans each year.

About Xoft^® Axxent^® Electronic Brachytherapy System^®
The Xoft System is an isotope-free radiation treatment cleared by the U.S.
Food and Drug Administration and CE marked in the EU for use anywhere in the
body, including for the treatment of early stage breast cancer, endometrial
cancer, cervical cancer and skin cancer. It utilizes a proprietary
miniaturized x-ray as the radiation source that delivers precise treatment
directly to cancerous areas while sparing healthy tissue and organs. A
post-market study is underway to assess the safety and efficacy of
Intraoperative Radiation Therapy with the Xoft System. Xoft, Inc. is a wholly
owned subsidiary of iCAD, Inc. For more information about Xoft visit
www.xoftinc.com.

About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow solutions and
radiation therapies for the early identification and treatment of common
cancers. iCAD offers a comprehensive range of high-performance, upgradeable
CAD solutions for mammography and advanced image analysis and workflow
solutions for Magnetic Resonance Imaging, for breast and prostate cancers and
Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers
radiation treatment for early-stage breast cancer that can be administered in
the form of intraoperative radiation therapy or accelerated partial breast
irradiation. The Xoft System is also cleared for the treatment of non-melanoma
skin cancer, cervical cancer and endometrial cancer. For more information,
call 877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995:
Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the Company’s
ability to identify a replacement for the Axxent FlexiShield Mini, the risks
relating to the Company’s acquisition of Xoft including, the expected benefits
of the acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”,
“likely”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under
no obligation to provide any updates to any information contained in this
release. For additional disclosure regarding these and other risks faced by
iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.

Contact:

For iCAD
Kevin Burns, 937-431-7967
kburns@icadmed.com
or
For iCAD investor relations
LHA
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
For iCAD media inquiries\
Schwartz MSL
Helen Shik, 781-684-0770
iCAD@schwartzmsl.com